➤ Subscribe for Complete Access

Flexible subscription options to meet your unique needs…

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
McKesson
Harvard Business School
Boehringer Ingelheim

Last Updated: November 27, 2021

DrugPatentWatch Database Preview

Patent: 10,280,208

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,280,208
Title:TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Inventor(s): Zang; Xingxing (New York, NY), Chinai; Jordan M. (Bronx, NY), Janakiram; Murali (Brooklyn, NY), Almo; Steven C. (Pelham, NY), Fiser; Andras (New York, NY)
Assignee: Albert Einstein College of Medicine (Bronx, NY)
Application Number:15/300,294
Patent Claims:see list of patent claims

Details for Patent 10,280,208

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Csl Behring Ag CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN immune globulin intravenous (human) For Injection 102367 2000-07-27 ⤷  Try it Free 2034-04-30
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 2007-07-26 ⤷  Try it Free 2034-04-30
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 2009-10-02 ⤷  Try it Free 2034-04-30
Csl Behring Ag PRIVIGEN immune globulin intravenous (human), 10% liquid Injection 125201 2013-02-07 ⤷  Try it Free 2034-04-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Moodys
Baxter
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.